Form 8-K - Current report:
SEC Accession No. 0001104659-24-104920
Filing Date
2024-10-01
Accepted
2024-10-01 16:05:16
Documents
14
Period of Report
2024-09-30
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2425273d1_8k.htm   iXBRL 8-K 28932
2 EXHIBIT 3.1 tm2425273d1_ex3-1.htm EX-3.1 6884
  Complete submission text file 0001104659-24-104920.txt   215068

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bcli-20240930.xsd EX-101.SCH 3036
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bcli-20240930_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bcli-20240930_pre.xml EX-101.PRE 22373
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2425273d1_8k_htm.xml XML 3808
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

EIN.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36641 | Film No.: 241343238
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)